Viromed H1 FY26 net loss widens to €1.1 million; revenue rises 4.17% to €2.5 million
Bitget2026/09/28 10:31- Viromed Medical posted H1 2026 revenue of €2.5 million, up 4.17% from a year earlier.
- Net loss widened to €1.1 million from €0.8 million a year earlier.
- Equity climbed 43.9% to €9.5 million, lifting the equity ratio to 67.6% from 39.9%.
- Management attributed the earnings trend to expenses for the PulmoPlas study and ViroCAP med approval and launch.
- Confirmed full-year 2026 guidance for a significant increase in revenue and net income; ViroCAP med sales started in July.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Synopsys (SNPS.US) partners with OpenAI to develop AI models for chip design, revenue-sharing model drives stock price up by 7%
On Wednesday, chip design software provider Synopsys (SNPS.US) announced that it has reached a partnership agreement with OpenAI. Both parties will jointly develop AI models for the chip business and share related revenues.
BoJ Summary of Opinions: Member says appropriate to keep raising rates in line with economy, price
Rio Tinto secures Bell Bay aluminum smelter operations till 2031
The British Pound rallies on a UK growth upgrade and gives more than half back
Crypto prices
More
